Page 222 - Read Online

Page 16 of 16 Cardinale et al. Hepatoma Res 2018;4:20 I http://dx.doi.org/10.20517/2394-5079.2018.46

HPB (Oxford) 2015;17:669-80.
128. Chen J, He J, Deng M, Wu HY, Shi J, Mao L, Sun Q, Tang M, Fan XS, Qiu YD, Huang Q. Clinicopathologic, radiologic, and molecular
study of 23 combined hepatocellular-cholangiocarcinomas with stem cell features, cholangiolocellular type. Hum Pathol 2017;64:118-27.
129. Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD, Thillainayagam
AV, Thomas HC, Wasan H; British Society of Gastroenterology. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an
update. Gut 2012;61:1657-69.
130. Bledsoe JR, Shinagare SA, Deshpande V. Difficult diagnostic problems in pancreatobiliary neoplasia. Arch Pathol Lab Med
2015;139:848-57.
131. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J
Hepatol 2009;51:237-67.
132. Lindor KD, Kowdley KV, Harrison ME; American College of Gastroenterology. ACG clinical guideline: primary sclerosing cholangitis.
Am J Gastroenterol 2015;110:646-59; quiz 660.
133. Navaneethan U, Njei B, Lourdusamy V, Konjeti R, Vargo JJ, Parsi MA. Comparative effectiveness of biliary brush cytology and intraductal
biopsy for detection of malignant biliary strictures: a systematic review and meta-analysis. Gastrointest Endosc 2015;81:168-76.
134. Arbelaiz A, Azkargorta M, Krawczyk M, Santos-Laso A, Lapitz A, Perugorria MJ, Erice O, Gonzalez E, Jimenez-Agüero R, Lacasta A,
Ibarra C, Sanchez-Campos A, Jimeno JP, Lammert F, Milkiewicz P, Marzioni M, Macias RIR, Marin JJG, Patel T, Gores GJ, Martinez
I, Elortza F, Falcon-Perez JM, Bujanda L, Banales JM. Serum extracellular vesicles contain protein biomarkers for primary sclerosing
cholangitis and cholangiocarcinoma. Hepatology 2017;66:1125-43.
135. Alvaro D. The challenge of cholangiocarcinoma diagnosis: the turning point is in extracellular vesicles? Hepatology 2017;66:1029-31.
136. Primrose JN, Fox R, Palmer DH, Prasad R, Mirza D, Anthoney DA, Corrie P, Falk S, Wasan HS, Ross PJ, Wall LR, Wadsley J, Evans
TRJ, Stocken D, Praseedom R, Cunningham D, Garden OJ, Stubbs C, Valle JW, Bridgewater JA. Adjuvant capecitabine for biliary tract
cancer: the BILCAP randomized study. J Clin Oncol 2017;35 Suppl 15:abstr4006.
137. Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, El-Khoueiry A,
Kelley RK, Borbath I, Choo SP, Oh DY, Philip PA, Chen LT, Reungwetwattana T, Van Cutsem E, Yeh KH, Ciombor K, Finn RS, Patel A,
Sen S, Porter D, Isaacs R, Zhu AX, Abou-Alfa GK, Bekaii-Saab T. Phase II study of BGJ398 in patients with FGFR-altered advanced
cholangiocarcinoma. J Clin Oncol 2018;36:276-82.
138. Bragazzi MC, Ridola L, Safarikia S, Matteo SD, Costantini D, Nevi L, Cardinale V. New insights into cholangiocarcinoma: multiple
stems and related cell lineages of origin. Ann Gastroenterol 2018;31:42-55.
139. Rycaj K, Tang DG. Cell-of-origin of cancer versus cancer stem cells: assays and interpretations. Cancer Res 2015;75:4003-11.
140. Visvader JE. Cells of origin in cancer. Nature 2011;469:314-22.
141. Cardinale V, Wang Y, Carpino G, Reid LM, Gaudio E, Alvaro D. Mucin producing cholangiocarcinoma might derive from biliarytree
stem/progenitor cells located in peribiliary glands. Hepatology 2012;55:2041-2.
142. Yamashita T, Wang XW. Cancer stem cells in the development of liver cancer. J Clin Invest 2013;123:1911-8.
143. Raggi C, Invernizzi P, Andersen JB. Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: molecular networks
and biological concepts. J Hepatol 2015;62:198-207.
144. Chen WT, Tseng CC, Pfaffenbach K, Kanel G, Luo B, Stiles BL, Lee AS. Liver-specific knockout of GRP94 in mice disrupts cell
adhesion, activates liver progenitor cells, and accelerates liver tumorigenesis. Hepatology 2014;59:947-57.
145. Vander Borght S, Komuta M, Libbrecht L, Katoonizadeh A, Aerts R, Dymarkowski S, Verslype C, Nevens F, Roskams T. Expression of
multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may
reflect a progenitor cell origin. Liver Int 2008;28:1370-80.
146. Govaere O, Komuta M, Berkers J, Spee B, Janssen C, de Luca F, Katoonizadeh A, Wouters J, van Kempen LC, Durnez A, Verslype C,
De Kock J, Rogiers V, van Grunsven LA, Topal B, Pirenne J, Vankelecom H, Nevens F, van den Oord J, Pinzani M, Roskams T. Keratin
19: a key role player in the invasion of human hepatocellular carcinomas. Gut 2014;63:674-85.
147. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012;21:283-96.
148. Moeini A, Sia D, Zhang Z, Camprecios G, Stueck A, Dong H, Montal R, Torrens L, Martinez-Quetglas I, Fiel MI, Hao K, Villanueva
A, Thung SN, Schwartz ME, Llovet JM. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct
molecular entity. J Hepatol 2017;66:952-61.
149. Wei M, Lü L, Lin P, Chen Z, Quan Z, Tang Z. Multiple cellular origins and molecular evolution of intrahepatic cholangiocarcinoma.
Cancer Letters 2016;379:253-61.